NEWS HIGHLIGHTS
Published Studies Related to Ca-Dtpa (Pentetate)
Subclinical carotid atherosclerosis: short-term natural history of lipid-rich
necrotic core--a multicenter study with MR imaging. [2013]
plaques by examining the placebo group of a multicenter clinical trial... CONCLUSION: Serial MR imaging of the carotid artery allowed observation of
Effect of hydroxyurea treatment on renal function parameters: results from the
multi-center placebo-controlled BABY HUG clinical trial for infants with sickle
cell anemia. [2012]
CONCLUSION: Treatment with hydroxyurea for 24 months did not influence GFR in
Carotid artery atherosclerosis: effect of intensive lipid therapy on the vasa vasorum--evaluation by using dynamic contrast-enhanced MR imaging. [2011.07]
PURPOSE: To investigate whether short-term, intensive lipid therapy leads to changes in microvascular characteristics, as measured by using dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging... CONCLUSION: These findings suggest that DCE MR imaging may be a useful imaging method for the assessment of the therapeutic response of the vasa vasorum in patients with atherosclerotic plaque.
Lower limb vascular disease in diabetic patients: a study with calf compression contrast-enhanced magnetic resonance angiography at 3.0 Tesla. [2011.06]
RATIONALE AND OBJECTIVES: To retrospectively analyze the significance of 3.0-T contrast-enhanced (CE) magnetic resonance angiography (MRA) with calf compression in the lower limbs of diabetic patients with peripheral vascular disease... CONCLUSION: Calf compression with 3.0-T CE-MRA was convenient and practical and could improve image quality and diagnostic accuracy in diabetic patients with peripheral vascular disease by reducing venous overlap. Copyright (c) 2011 AUR. Published by Elsevier Inc. All rights reserved.
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). [2011.05.14]
BACKGROUND: Sickle-cell anaemia is associated with substantial morbidity from acute complications and organ dysfunction beginning in the first year of life. Hydroxycarbamide substantially reduces episodes of pain and acute chest syndrome, admissions to hospital, and transfusions in adults with sickle-cell anaemia. We assessed the effect of hydroxycarbamide therapy on organ dysfunction and clinical complications, and examined laboratory findings and toxic effects... INTERPRETATION: On the basis of the safety and efficacy data from this trial, hydroxycarbamide can now be considered for all very young children with sickle-cell anaemia. FUNDING: The US National Heart, Lung, and Blood Institute; and the National Institute of Child Health and Human Development. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Clinical Trials Related to Ca-Dtpa (Pentetate)
Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR) [Recruiting]
The purpose of this study is to validate in comparison to a reference method (inuline) two
novel non-radioactive biomarkers for glomerular filtration rate (GFR) measurement in
chronic-kidney disease (CKD) patients and in healthy volunteers: Calcium-EDTA and Gd-DOTA.
Prolonged Gadolinium Retention After MRI Imaging [Not yet recruiting]
The researchers propose to investigate the prevalence of gadolinium in the urine of patients
with a prior gadolinium-enhanced MRI before and after a edetate calcium disodium challenge.
Moreover, will investigate if there is any correlation of gadolinium urine levels with
levels of endogenous (e. g zinc) and xenobiotic metals.
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia [Completed]
This study will examine the use of a radioactive monoclonal antibody called yttrium
90-labeled humanized anti-Tac (90 Y-HAT) for treating certain cancers. Monoclonal antibodies
are genetically engineered proteins made in large quantities and directed against a specific
target in the body. The anti-Tac antibody in this study is targeted to tumor cells and is
tagged (labeled) with a radioactive substance called Yttrium-90 (Y-90). The study will
determine the maximum tolerated dose of 90Y-HAT and examine its safety and effectiveness.
Patients 18 years of age and older with Hodgkin's disease, non-Hodgkin's lymphoma and
lymphoid leukemia who have proteins on their cancer cells that react with anti-Tac may be
eligible for this study. Candidates are screened with a medical history and physical
examination, blood and urine tests, electrocardiogram (EKG), chest x-ray, CT scan or
ultrasound of the abdomen, PET scan of the neck and body, and skin test for immune
reactivity to antigens (similar to skin tuberculin test).
Before beginning treatment, participants may undergo additional procedures, including the
following:
- Patients with suspicious skin lesions have a skin biopsy. An area of skin is numbed and
a circular piece of skin about 1/4-inch diameter is removed with a cookie cutter-like
instrument.
- Patients with hearing loss have a hearing test.
- Patients with neurological symptoms have a lumbar puncture (spinal tap). A local
anesthetic is given and a needle is inserted in the space between the bones in the
lower back where the cerebrospinal fluid circulates below the spinal cord. A small
amount of fluid is collected through the needle.
- Patients who have not had a bone marrow biopsy within 6 months of screening also
undergo this procedure. The skin and bone at the back of the hip are numbed with a
local anesthetic and a small piece of bone is withdrawn through a needle.
Patients receive 90 Y-HAT in escalating doses to determine the highest dose that can be
safely given. The first group of three patients receives a low dose and, if there are no
significant side effects at that dose, the next three patients receive a higher dose. This
continues with subsequent groups until the maximum study dose is reached. 90 Y-HAT is given
through a vein (IV) over a 2-hour period. In addition, a drug called Ca-DTPA is given via IV
over 5 hours for 3 days to help reduce the side effects of the 90Y-HAT. In some patients,
the 90 Y-HAT may also be attached to a radioactive metal called Indium-111 to monitor what
happens to the injected material. During infusion of the drug, patients undergo PET scanning
to trace the path of the injected material in the body. For this procedure, the patient lies
in the scanner, remaining in one position during the entire infusion.
Blood and urine specimens are collected periodically over a 6-week period following the
infusion to determine the level of the radioactive antibody. Bone marrow, lymph node, or
skin biopsies may be done to determine how much of the antibody entered these sites.
Patients whose disease remains stable or improves with therapy may receive up to six more
infusions of 90 Y-HAT , with at least a 6-week interval between treatments.
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies [Withdrawn]
RATIONALE: Antimicrobial solution comprising trimethoprim-sulfamethoxazole, edetate calcium
disodium, and ethanol may help prevent blockages and infections from forming in patients
with central venous access catheters or peripheral venous catheters.
PURPOSE: This randomized trial is studying an antimicrobial solution or saline solution in
maintaining catheter patency and preventing catheter-related blood infections in patients
with malignancies.
Monoclonal Antibody Therapy in Treating Patients With Leukemia [Completed]
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody
plus pentetic acid calcium in patients with leukemia.
|
